|
GBE1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62458935193399E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
5.56870000112397E-08 |
| Normal-vs-Stage3 |
2.95319324550292E-14 |
| Normal-vs-Stage4 |
2.41184849869569E-12 |
| Stage1-vs-Stage2 |
2.861400E-01 |
| Stage1-vs-Stage3 |
4.824400E-01 |
| Stage1-vs-Stage4 |
3.405800E-01 |
| Stage2-vs-Stage3 |
1.686970E-01 |
| Stage2-vs-Stage4 |
1.100220E-01 |
| Stage3-vs-Stage4 |
7.185400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
2.29960000042162E-07 |
| Normal-vs-Asian |
2.9490854203118E-12 |
| Caucasian-vs-AfricanAmerican |
4.783400E-01 |
| Caucasian-vs-Asian |
7.297800E-01 |
| AfricanAmerican-vs-Asian |
3.293000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.11022302462516E-16 |
| Normal-vs-Female |
1.62436730732907E-12 |
| Male-vs-Female |
3.283400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.66211489016632E-12 |
| Normal-vs-Age(41-60Yrs) |
1.11022302462516E-16 |
| Normal-vs-Age(61-80Yrs) |
1.67021951824609E-12 |
| Normal-vs-Age(81-100Yrs) |
3.556400E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.779600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.812400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.056000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.071200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.113800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.506000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.610400E-01 |
| Classical-VS-Follicular |
6.055600E-01 |
| Classical-VS-Other |
2.275800E-01 |
| Classical-VS-Normal |
1.62436730732907E-12 |
| Tall-VS-Follicular |
3.864400E-01 |
| Tall-VS-Other |
3.482600E-01 |
| Tall-VS-Normal |
2.94439994608098E-09 |
| Follicular-VS-Other |
9.121600E-02 |
| Follicular-VS-Normal |
1.14939999740216E-08 |
| Other-VS-Normal |
4.1057000000011E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
2.95319324550292E-13 |
| N0-vs-N1 |
3.769800E-01 |
|
|
